Shares of Metsera, Inc. (NASDAQ:MTSR – Get Free Report) traded down 4% on Thursday . The company traded as low as $28.20 and last traded at $28.68. 22,857 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 566,749 shares. The stock had previously closed at $29.86.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the company. Bank of America started coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target for the company. Evercore ISI began coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Guggenheim began coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target for the company. Finally, Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company.
Check Out Our Latest Research Report on MTSR
Metsera Price Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- What Investors Need to Know to Beat the Market
- MarketBeat Week in Review – 03/17 – 03/21
- What is MarketRank™? How to Use it
- FedEx Delivers Another Crushing Blow to Its Stock Price
- 3 Stocks to Consider Buying in October
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
